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Guideline-recommended minimum 3-year course of therapy.
Among the 308 patients receiving IT who were included in clin-
ical and economic subanalyses, average IT cost was $20 (SD $23)
per administration and $468 (SD $543) over the treatment
course. Pharmacy, outpatient and inpatient costs signiﬁcantly
decreased in the 6 months following completion of IT versus the
6 months prior to IT initiation (−$78, p = 0.0125; −$273, p =
0.0005; −$2123, p = 0.0092 respectively). CONCLUSION: We
found wide variation in IT delivery by sex and race. Despite the
preponderance of premature IT discontinuation among patients
in our study, signiﬁcant cost savings were demonstrated. Find-
ings suggest that patients with AR and the health care systems
that provide care to these patients may beneﬁt from broader
access and improved adherence to IT.
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OBJECTIVES: To assess in a managed care setting the sub-acute
lack of asthma control (SALAC) identiﬁed by excess short-acting
ß2-agonist (SABA) use or clinic visits but not necessarily associ-
ated with acute asthma exacerbations. METHODS: An admin-
istrative claims database containing 8.8 million lives was
analyzed over 4 years (June 2000–May 2004). Patients aged ≥12
years with an ICD-9 code for asthma and ≥2 claims/year for
asthma medication were included; those with other signiﬁcant
respiratory conditions were not. SALAC was deﬁned as >4 clinic
visits for asthma/year or ≥2/quarter, or >5 SABA prescrip-
tions/year. Acute asthma exacerbations were deﬁned as asthma-
related emergency department visits, hospitalizations, or oral
corticosteroid bursts. SALAC rates during years 2–4 were com-
pared for patients who had loss of control during year 1 with
patients who did not. RESULTS: Of 3998 patients (mean age =
41 years, 65% female) who met the study criteria, only 42% had
an acute exacerbation but 70% had SALAC in the 4-year period
(63% excess clinic visits/year, 36% excess SABA/year); 22% had
SALAC in only 1 of the 4 years, 16% in 2 of the 4 years, 14%
in 3 of the 4 years, and 18% in all 4 years. Patients experienc-
ing SALAC in year 1 were more likely to do so again in years
2–4 vs. all other patients (83% v. 47%; p < 0.001). SALAC
rates/year changed little over the 4-year period (year 1: 44%;
year 2: 45%; year 3: 42%; year 4: 37%). CONCLUSION: A
sub-acute loss of asthma control (SALAC) in 1 year predicts
SALAC in a subsequent year. SALAC occurred in more than two
thirds of patients at some point and occurred every year in
almost one ﬁfth. Asthma control is also lacking in many patients
who did not have an acute exacerbation.
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OBJECTIVE: In their 2007 guidelines, the National Asthma
Education and Prevention Program (NAEPP) recommends
assessing a patient’s level of asthma control to determine an
appropriate management strategy. We sought to describe the
levels and transition patterns of asthma control as deﬁned by the
new NAEPP guidelines for an adult asthma cohort with severe
or difﬁcult-to-treat disease. METHODS: We used The Epidemi-
ology and Natural History of Asthma: Outcomes and Treatment
Regimens (TENOR) adult cohort to describe their NAEPP
informed levels of asthma control. TENOR was a three year,
multicenter, prospective study of patients with severe or difﬁcult-
to-treat asthma that received standard of care. TENOR adults
were semi-annually categorized into three levels of asthma
control: controlled, partly controlled, and uncontrolled. We
measured impairment with spirometry and the validated Asthma
Therapy Assessment Questionnaire (ATAQ) and measured exac-
erbation risk with health care utilization outcomes. RESULTS:
A total of 3488 adults (≥18 years of age) had a mean follow-up
of 25 months. At baseline, 12.5% were controlled, 34.9% were
partly controlled, and 52.6% were uncontrolled. Out of 15,569
control assessments across all visits, 15.3% were controlled,
35.0% were partly controlled, and 49.7% were uncontrolled.
Data was missing on an additional 1476 (8.7%) observations
across all completed visits. Six month transition patterns of
control yielded: 63.4% of controlled patients remained con-
trolled, 65.2% of partly controlled patients remained partly 
controlled, and 82.4% of uncontrolled patients remained uncon-
trolled. CONCLUSIONS: The results suggest that the majority
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of adults in TENOR do not achieve asthma control and that a
considerable proportion of patients transition from one level of
asthma control to another over six months. This and additional
research that quantiﬁes the relationship between control and util-
ities and costs could aid in the development of an asthma policy
model for severe or difﬁcult-to-treat asthma.
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OBJECTIVES: Excessive use of short acting bronchodilators
worsens asthma control. This study hypothesizes that people
with no prescription drug insurance coverage tend to rely more
on short acting bronchodilators (SAB) than controller drugs and
consequently have higher number of Emergency Department
(ED) visits. METHODS: This study utilized 2004 Medical
Expenditure Panel Survey (MEPS)data. Asthma patients (ICD
code: 493) were identiﬁed from the “medical conditions ﬁle.”
Prescription drug insurance coverage and ED visits were identi-
ﬁed from the “house hold component of MEPS.” Multiple logis-
tic regression analysis was used to estimate associative risks of
ED visits and SAB use among asthmatic patients with no pre-
scription drug insurance coverage. RESULTS: A total of 14
million individuals were estimated to have asthma in U.S. in the
year 2004. Amongst them 6.21 million (44.2%) did not have
prescription drug coverage. A total of 3.06 million ED visits were
reported by people without prescription drug coverage compared
to 2.53 million ED visits by individuals having prescription drug
coverage. The people with no prescription drug coverage had a
noticeably higher risk of ED visit. (Odds Ratio (OR) = 1.498;
95% CI: 1.494 to 1.502). The people with no prescription drug
coverage are more likely to use SAB (ﬁlled at least 10 prescrip-
tions during the year) compared to those who had prescription
drug coverage. (OR = 2.544; 95% CI: 2.534 to 2.554) CON-
CLUSION: Asthma patients without prescription drug insurance
coverage have higher number of ED visits compared to patients
with insurance coverage. There is a signiﬁcant association of pre-
scription drug non-coverage and overuse of short acting bron-
chodilators. We conclude that the policy changes to improve
access to controller drugs will reduce number of ED visits and
over utilization of short acting bronchodilators.
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OBJECTIVES: Although parents are often asked to report their
children’s medication use for epidemiological and health eco-
nomic evaluations, the accuracy of medication reports from
parental proxies is unknown. The objective was to assess agree-
ment between parent report and medical record for pediatric
asthma patients. METHODS: A retrospective analysis compared
parent and medical chart data for reports of current asthma med-
ication name and strength in 99 asthmatic children recruited
from outpatient practices of a pediatric respirologist and an aller-
gist. RESULTS: A total of 279 asthma medications were reported
with an average of 2.8 ± 1.2 asthma medications per child.
Perfect agreement between reported and charted asthma med-
ication names and strengths was found in 4% of the medical
charts and occurred for 33% of reported medications. Medica-
tion names were found in the medical chart for 85% (238/279)
of reported medications and a medication strength was located
in the medical chart for 52% (123/238) of these. Parents
reported a medication strength that did not match the chart for
24% (29/123) of the asthma medications for which strengths
were found in the chart. Signiﬁcantly more medication strengths
were found in the medical chart for inhaled corticosteroids
(90/100) than for short-acting beta agonists (9/95) (p < 0.03).
Of the 90 inhaled corticosteroids for which strengths were
recorded in the medical chart, 70 (78%) matched the parent
report. Of the 9 short-acting beta agonists for which strengths
were recorded in the medical chart, 4 matched the parent report.
This difference in agreement was signiﬁcant (p < 0.03). CON-
CLUSION: Parents may be able to provide more detailed infor-
mation about their child’s current asthma medications than the
medical chart as many asthma medication strengths were not
recorded in the medical chart.
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OBJECTIVES: This study attempted to determine if select
patient and physician demographic variables are predictors of
the prescribing of asthma pharmacotherapy in the ambulatory
patient population of the United States. Another aim of this
study was to evaluate if physician prescribing behavior of asthma
pharmacotherapy was in compliance with the recommendations
of the National Heart, Lung & Blood Institute’s National
Asthma Education and Prevention Program Expert Panel 
2 national asthma guidelines. METHODS: This study was a 
retrospective cross-sectional study that used data from the
National Ambulatory Medical Care Survey (NAMCS) from
1998 through 2004. The weighted population sample size of the
study was 82,020,318 patients. Speciﬁc patient demographic
variables, physician demographic variables and asthma medica-
tions prescribed were extracted from the dataset and analyzed
using logistic regression procedures. RESULTS: The major
ﬁnding from the study was that physicians did not seem to be
adhering to the EPR-2 pharmacotherapy guidelines. Another
major ﬁnding from this study was the fact that there were vul-
nerable sub-populations of asthma patients that were receiving
sub-optimal asthma pharmacotherapy. It was also found that
patients who were non-white and non-African American were
also less likely to receive optimal asthma pharmacotherapy (all
p < 0.05). The majority of these patients were of Asian origin.
These individuals were less likely to be prescribed controller
medications and more likely to be prescribed SABA agents when
compared to whites. Patient status, physician specialty, owner-
ship status and physician employment status were important
variables in certain aspects of asthma pharmacotherapy. CON-
CLUSION: It appears that a more concerted effort needs to be
undertaken to improve physician adherence to the EPR-2 guide-
lines, especially in the prescribing of asthma pharmacotherapy.
There is also a need to address the disparities observed in the
prescribing of asthma pharmacotherapy in vulnerable, under-
served populations.
